BioSpace News Archive

Achieved regulatory and ethics authorization for Phase 2 dose ranging trial for EDP1815 in moderate psoriasis in the U.S., UK, and EU; trial initiation expected in 3Q 2020 with interim data expected by mid-2021

Tonix Pharmaceuticals Holding Corp. announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation during the SNN Network Virtual Investor Conference on Thursday, August 6, 2020, at 10:00 a.m. ET.

Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will present initial clinical data on the first five patients from Part B of the ongoing Phase 1/2a study, which explores the combination of Genocea’s neoantigen vaccine, GEN-009 and checkpoint inhibitor-based regimens in advanced solid tumors.

The global Phase 2/3 study will enroll up to 270 patients with severe COVID-19 across 40 clinical sites; The study has been approved in the UK and Russia and is under review in Italy, Brazil and Mexico

Lantern Pharma announced its financial results for the second quarter ended June 30, 2020, and provided an update on its R&D pipeline and other corporate developments.

Cerner selects Nuance’s virtual assistant platform to reduce the cognitive burden on care teams and improve patient experience

Phase 1 Single Ascending Dose Study is Intended to Support the Clinical Development of SYN-020 in Multiple Indications

Seegene, Inc. announced that U.S. Food and Drug Administration has further expanded the emergency use authorization for its Allplex™ 2019-nCoV Assay, a real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible for the COVID-19 disease.

Initiation of triple combination study accelerating the evaluation of the DNAM axis hypothesis on-track for 2H 2020

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, announced the promotion of Antoine ‘Tony’ Awad to the position of Chief Operating Officer.